Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Recurrence 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Sarcoma 1Ovarian Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloproliferative Disorders 1Lymphoma 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Colorectal Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 27Irinotecan 8Filgrastim 8Carmustine 7Carboplatin 7Surgical Procedures, Operative 6O(6)-benzylguanine 6Flucytosine 6sargramostim 4Vorinostat 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4vocimagene amiretrorepvec 3lonafarnib 3Radiosurgery 3Lenalidomide 3Imatinib Mesylate 3Genetic Therapy 3Erlotinib Hydrochloride 3Cyclophosphamide 3Bortezomib 3temsirolimus 2cediranib 2aldesleukin 2Vincristine 2Vinblastine 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Oligodendroglioma × plerixafor × Clear all
NCT01339039 2017-11-17

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Dana-Farber Cancer Institute

Phase 1 Terminated
26 enrolled
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡